Contact Us

Real-world Evidence Publications

  • Journal, Multiple Sclerosis, Real-world Evidence

Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments

See entire work

Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments

See entire work
Muros-Le Rouzic, E | Heer, Y | Yiu, S | Tozzi, V | Braune, S | van Hövell, P | Bergmann, A | Bernasconi, C | Model, F | Craveiro, L | & NTD study group Journal of Central Nervous System Disease (2024)
Background: Clinical trials comparing the efficacy of ocrelizumab (OCR) with other disease-modifying therapies (DMTs) other than interferon (IFN) β-1a in relapsing multiple sclerosis (RMS) are lacking. Objectives. To compare the treatment effect of OCR vs six DMTs’ (IFN β-1a, glatiramer acetate, fingolimod, dimethyl fumarate, teriflunomide, natalizumab) treatment pathways used in clinical practice by combining clinical trial and real-world data.
  • Journal, Migraine, Real-world Evidence

Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies–insights from the German NeuroTransData registry

See entire work

Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies–insights from the German NeuroTransData registry

See entire work
Hong, JB | Israel-Willner, H | Peikert, A | Schanbacher, P | Tozzi, V | Köchling, M | … & NTD Study Group. The Journal of Headache and Pain (2024)
Background. Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway have shown good efficacy in migraine prophylaxis. However, a subset of patients does not respond to the first mAb treatment and switches among the available mAbs. The goal of this study is to characterize the switching pattern of migraine patients treated with anti-CGRP(-receptor, -R) mAbs, and to describe the headache burden of those who did not switch, switched once, and switched twice.
  • Journal, Multiple Sclerosis, Real-world Evidence

Cost and quality of life of disability progression in multiple sclerosis beyond EDSS: Impact of cognition, fatigue, and limb impairment

See entire work

Cost and quality of life of disability progression in multiple sclerosis beyond EDSS: Impact of cognition, fatigue, and limb impairment

See entire work
Wasem, J | Heer, Y | Karamasioti, E | Muros-Le Rouzic, E | Marcelli, G | di Maio, D | Braune, S | Kobelt, G | & Dillon, P. PharmacoEconomics – Open (2024)
Background and Objective: Understanding the socioeconomic burden of multiple sclerosis (MS) is essential to inform policymakers and payers. Real-world studies have associated increasing costs and worsening quality of life (QoL) with disability progression. This study aims to further evaluate the impact of cognition, fatigue, upper and lower limb function (ULF, LLF) impairments, and disease progression per Expanded Disability Status Scale (EDSS) level, on costs and QoL.
  • Conference, Multiple Sclerosis, Real-world Evidence

Confirmed disability improvement and progression in nonactive progressive multiple sclerosis patients in a real-world registry

See entire work

Confirmed disability improvement and progression in nonactive progressive multiple sclerosis patients in a real-world registry

See entire work
Watson Crystal, Jarecki, J. B | Barlev, A | Heer, Y | Braune, S | Bogdanovich, S | Stahl, N | Bergmann, A | & Kresa-Reahl, K. Multiple Sclerosis Journal (2024)
Background: Information on the natural history of disability progression/improvement in nonactive progressive multiple sclerosis (naPMS) is lacking. Real-world data from the German NeuroTransData (NTD) MS registry were used to describe the natural history of disability changes in an naPMS population. Objectives: Characterize confirmed disability improvement (CDI) and confirmed disability progression (CDP) over time in naPMS patients using the NTD registry.
  • Journal, Multiple Sclerosis, Real-world Evidence

Erkrankte nicht mit DiGA alleine lassen, Digitale Behandlung bei MS

See entire work

Erkrankte nicht mit DiGA alleine lassen, Digitale Behandlung bei MS

See entire work
Bergmann, A | Kausch, U | Köchling, M | van Hövell, P | Wolf, A. NeuroTransmitter (2023)
In einer Verlaufsbeobachtung des NTD-Netzwerkes wurde Personen mit MS eine digitale Gesundheitsanwendung verschrieben. Patientinnen und Patienten wurden zu ihrem Gebrauch der Anwendung befragt.
  • Journal, Multiple Sclerosis, Real-world Evidence

The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry

See entire work

The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry

See entire work
Braune, S | Bluemich, S | Bruns, C | Dirks, P | Hofmann, J | Heer, Y | Muros-Le Rouzic, E | Bergmann, A | NTD Study Group //10.1186/s12883-023-03273-9 (2023)
Background: Primary progressive multiple sclerosis (PPMS) is characterised by gradual worsening of disability from symptom onset. Knowledge about the natural course of PPMS remains limited. Methods: PPMS patients from the German NeuroTransData (NTD) MS registry with data from 56 outpatient practices were employed for retrospective cross-sectional and longitudinal analyses. The cross-sectional analysis included a contemporary PPMS cohort with a documented visit within the last 2 years before index date (1 Jan 2021).